Yahoo Finance

Stifel upgraded Denali Therapeutics (DNLI) to Buy from Hold with a $37 price target Denali recently aligned with the FDA to file for accelerated approval for their lead candidate DLN310/tividenofusp alfa in MPS IIA/Hunter syndrome with a BLA submission expected early-2025, which “represents a major win,” the analyst tells investors. Though the firm thinks DNL310 should get approved, there are “still a number of outstanding questions,” the analyst added.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on DNLI:

• Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122

• Denali Therapeutics management to meet with B. Riley

• Denali Therapeutics Advances Brain Disease Therapies

• Denali Therapeutics sees Fy24 opex increase of 5%-10% year-over-year

• Denali Therapeutics reports Q3 EPS (63c), consensus (61c)